Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …

Major developments in the treatment of multiple myeloma (MM) over the past decade have
led to a continued improvement in survival. Significant progress has been made with deeper …

Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

PURPOSE The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide,
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …

The role of the immune microenvironment in maintaining disease remission in patients with
multiple myeloma (MM) is not well understood. In this study, we comprehensively profile the …

PURPOSE High levels of circulating tumor plasma cells (CTC-high) in patients with multiple
myeloma are a marker of aggressive disease. We aimed to confirm the prognostic impact …

Background Lenalidomide is a cornerstone of maintenance therapy in patients with newly
diagnosed multiple myeloma after autologous stem-cell transplantation. We aimed to …

PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal
gammopathy. It was formerly characterized by≥ 20% circulating plasma cells (CTCs) until …

The current standard of care model for newly diagnosed fit multiple myeloma (NDMM)
patients is the sequential treatment of induction, high dose melphalan, autologous stem cell …